Buy this cannabis stock for a double, analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $3.25 target on Organigram Holdings (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) in a M …
Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?
Canopy Growth (NASDAQ: CGC) has made considerable efforts to turn itself around. Over the past few years, the Canada-based cannabis company has significantly reduced its outstandi …
Canopy Growth Is One of the Market’s Most Polarizing Stocks: 3 Scenarios for the Next 12 Months
After years of heavy losses and repeated restructurings, Canopy Growth is showing early signs of stabilization.
Cannabis Revenue Decline Pressures Organigram Earnings Despite Germany Expansion (OGI)
Organigram reported weaker second-quarter revenue and profitability as vape and infused pre-roll sales slowed, while the company positioned its Sanity Group acquisition as a major international growth …
This weed stock is undervalued, analyst says
The analyst expects Trulieve to generate Adjusted EBITDA of US$401.1-million on revenue of US$1.178-billion in fiscal 2026, improving to US$415.8-million on revenue of US$1.221-billion in fiscal 2027.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Cannabis Stocks On NASDAQ Markets: A Guide For U.S.
Discover how U.S.-traded cannabis stocks work, what defines the cannabis universe on NASDAQ and OTC markets, and what U.S. investors typically consider.
Cannabis MSO Curaleaf prepares for uplisting on US stock exchanges
Curaleaf will execute a 1-for-3 reverse stock split positioning it to uplist to a U.S. stock exchange cannabis rescheduling creates an opening to do so.
Should you buy CGC stock after marijuana reclassification?
Canopy Growth Corporation CGC is back in focus as marijuana reclassification efforts revive investor interest in cannabis stocks. While the regulatory shift has improved sentiment across the sector, …
‘Devastating’: Retired firefighter says he lost most of his retirement savings investing in stocks that were targeted by a famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Forget SNDL: HITI is a Significantly Better Cannabis Stock
Every cannabis trader’s feed is buzzing about SNDL (NASDAQ:SNDL) because the company’s Q1 2026 release on April 28, 2026 delivered a tidy little EPS beat that retail can rally around. The underlying …
Prediction: Green Thumb Industries Stock Will Double Within 3 Years
Green Thumb is about as blue chip as it comes in the U.S. cannabis industry. The company has multiple potential catalysts that could drive its stock higher. One knock against Green Thumb, though, is …
Aurora Cannabis: Why I Like This Stock
Aurora Cannabis Inc. outlook: improving international revenue, margins, and net cash. Valuation suggests 64% upside to $5.58. Click for more on ACB stock.
The cannabis rescheduling is causing celebration — and confusion — as marijuana stocks sell off
Marijuana stocks sold off Thursday, after acting U.S. Attorney General Todd Blanche signed an order rescheduling FDA-approved and state-licensed medical cannabis products as a less harmful substance — a move that led to celebration but also confusion among industry...
Cannabis Stocks Soared—Than Sank. Here’s What Investors Need to Know.
Cannabis stocks and funds that hold them surged after the Trump administration moved it from the government most restrictive drug category to one that can be obtainable with a prescription.
Recent Comments